Communicating emerging, trusted scientific information to healthcare professionals (HCPs). Pfizer sponsored, intended for U.S. HCPs. Our community guidelines can be found here: https://t.co/CHDiNLQV7P
How could a JAKi influence skin microbiome in patients with M2S atopic dermatitis? Explore the association between changes in microbial diversity, clinical metrics and inflammatory and skin barrier markers. Read the full publication to learn more. https://t.co/ydmKeu6dpo
Explore the latest science in transthyretin amyloid cardiomyopathy (ATTR-CM) from Pfizer Medical at #ISA2026. Visit Pfizer Medical website to access scientific presentations and resources on diagnosis, quality of life, outcomes, and disease monitoring. https://t.co/bR73bFcmuw
Looking for clinical evidence in anticoagulation? Explore the new Pfizer Medical Knowledge Hub, featuring selected RCT and RWE study summaries in NVAF and VTE. Optimized for desktop, tablet & mobile, so the evidence goes wherever you go. https://t.co/TNwNPFa99q
How does baseline AD severity affect short- and long-term response to a JAKi across clinical and patient-reported outcomes? Read the results of a recently published exploratory post-hoc analysis in Dermatology and Therapy.
https://t.co/f7V9vfx8N2
New publication! How do long-term SALT score trajectories evolve in adolescents with severe alopecia areata? Explore findings from a post hoc analysis of the ALLEGRO clinical development program. Read the full publication to learn more. https://t.co/7NJ9OLDAhi
New publication! Explore findings from a Delphi consensus statement developed to provide expert recommendations for the management of severe alopecia areata. https://t.co/fgQVWmhSvz
New publication in the Journal of Endocrine Society reports 5 year data of a once-weekly treatment for pediatric growth hormone deficiency. https://t.co/radSUlUYfC
Watch the latest videos from Pfizer Hemophilia Medical, covering unmet needs, hemophilia care, insights on treatments from experts, and more. View the playlist here: https://t.co/nvi4ZaM3VN
How should vitiligo severity and relapse be defined? Explore findings from an international consensus statement developed to support consistent assessment in clinical care of vitiligo. https://t.co/GnukIk48mS
Read the results of an exploratory post-hoc analysis evaluating how well patients with moderate-to-severe AD maintained disease control on- and off-treatment with a JAKi. https://t.co/gU3SlO5bdO
Read about the post hoc exploratory analysis of pooled data assessing the effectiveness and tolerability of a CGRP receptor antagonist in Hispanic or Latino ethnicity adults for the acute treatment of migraine.
#neurotwitter
https://t.co/6P4yYuDBxw
Recent data at #ACR26: a JAK inhibitor in early active axial spondyloarthritis, long-term data in juvenile idiopathic arthritis, and the impact of idiopathic inflammatory myopathies. Explore the latest insights on Pfizer Medical.
https://t.co/75Cqv2xqPf
New real-world migraine study
The Migraine Insights in Diagnosis and Treatment (MIND) study, a retrospective cohort study of newly diagnosed with migraine in the US, describes diagnosis and treatment patterns over the 3 years after diagnosis.
Full article https://t.co/P6NlSIqa5B
New Publication!
How do a JAK inhibitor and biologic achieve skin clearance in chronic hand eczema? Explore findings from a prespecified exploratory analysis in adults with moderate-to-severe atopic dermatitis and CHE. https://t.co/sXNA76xppV
Join Pfizer at #ObesityWeek2026! Check out our poster presentations and visit our booth #601 to learn more. https://t.co/9U7XXLY3sJoin Pfizer at #ObesityWeek2026! Check out our poster presentations and visit our booth #601 to learn more. https://t.co/9U7XXLY3sJoin Pfizer at #ObesityWeek2026! Check out our poster presentations and visit our booth #601 to learn more. https://t.co/9U7XXLY3sJoin Pfizer at #ObesityWeek2026! Check out our poster presentations and visit our booth #601 to learn more. https://t.co/9U7XXLY3s9
This #NPWeek, Pfizer extends gratitude towards nurse practitioners for their contribution in managing patients with migraine.
Visit the JAANP resource center to learn more about Pfizerβs Migraine Management Toolkit on migraine diagnosis and management.
https://t.co/tsT8AI1577
NEW MIGRAINE DATA
Read more about the efficacy and safety of a nasal migraine therapy option for the acute treatment of #migraine in Asian adults. Explore the full findings here: https://t.co/1WLkptJBgc
Learn more about a Phase 3 trial demonstrating sustained growth and consistent safety profile of a once-weekly treatment of #pediatricGHD.
Explore the findings and clinical implications for long-term management.
https://t.co/7Qpyzs8sv9